TY - JOUR
T1 - Improvement of antiangiogenic cancer therapy by understanding the mechanisms of angiogenic factor interplay and drug resistance
AU - Cao, Yihai
AU - Zhong, Weide
AU - Sun, Yan
N1 - Funding Information:
Yihai Cao thank Sharon Lim for the artistic work. We regret that, owing to the space limitation, we am unable to cover all aspects of the large amount of basic and clinical research on this topic and to refer to all primary literatures and in many instances we have to cite to reviews. Yihai Cao's laboratory is supported by research grants from the Swedish Research Council, the Swedish Heart and Lung Foundation, the Swedish Cancer Foundation, the Karolinska Institute fund, the Karolinska Gender foundation, the Söderberg Foundation, European Union Integrated Projects of Angiotargeting Contract 504743 and European VascuPlug Contract STRP 013811.
PY - 2009/10
Y1 - 2009/10
N2 - Several antiangiogenic agents, including bevacizumab, sunitinib, and sorafenib, which mainly target the VEGF signaling system, have been approved for the treatment of human cancers. These drugs have been paired with conventional chemotherapeutic agents to treat different types of cancers, including colorectal and lung cancers; however, the patient response rate and resultant increase in overall survival time have been rather modest. The current antiangiogenic regimen is far from optimal. Improvements of therapeutic efficacy and minimization of adverse effects and drug resistance are urgent tasks that are most likely to be resolved by understanding the molecular mechanisms underlying tumor angiogenesis. The aim of this article is to discuss these clinically related issues, to highlight several recent examples of the complex interplays between tumor-produced angiogenic factors, and to propose a new paradigm for improvement of therapeutic intervention of tumor angiogenesis.
AB - Several antiangiogenic agents, including bevacizumab, sunitinib, and sorafenib, which mainly target the VEGF signaling system, have been approved for the treatment of human cancers. These drugs have been paired with conventional chemotherapeutic agents to treat different types of cancers, including colorectal and lung cancers; however, the patient response rate and resultant increase in overall survival time have been rather modest. The current antiangiogenic regimen is far from optimal. Improvements of therapeutic efficacy and minimization of adverse effects and drug resistance are urgent tasks that are most likely to be resolved by understanding the molecular mechanisms underlying tumor angiogenesis. The aim of this article is to discuss these clinically related issues, to highlight several recent examples of the complex interplays between tumor-produced angiogenic factors, and to propose a new paradigm for improvement of therapeutic intervention of tumor angiogenesis.
KW - Angiogenesis
KW - Cancer
KW - Drug resistance
KW - Growth factor
KW - Metastasis
UR - http://www.scopus.com/inward/record.url?scp=70349807690&partnerID=8YFLogxK
U2 - 10.1016/j.semcancer.2009.05.001
DO - 10.1016/j.semcancer.2009.05.001
M3 - Review article
C2 - 19481151
AN - SCOPUS:70349807690
SN - 1044-579X
VL - 19
SP - 338
EP - 343
JO - Seminars in Cancer Biology
JF - Seminars in Cancer Biology
IS - 5
ER -